Bispecific antibody-drug conjugates (BsADCs) are emerging as a cutting-edge approach in cancer therapy, combining bispecific antibody precision with antibody-drug conjugate potency.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.